Sickle Cell Disease Treatment Centers Act of 2026
- Sponsor
- Sen. Van Hollen, Chris [D-MD]
- Committees
- Health, Education, Labor, and Pensions Committee (primary)
- Last action
- Sep 23, 2026
Bottom line
The bill seeks to improve health outcomes and reduce disparities for individuals with sickle cell disease by funding integrated care networks, fostering national coordination, and strengthening data collection and public education.
What it actually does
This bill establishes a federal grant program to create Sickle Cell Disease Treatment Centers across the United States, utilizing a "hub-and-spoke" network model that integrates medical facilities with community-based organizations. It also mandates the creation of a National Sickle Cell Disease Coordinating Center and enhances the Centers for Disease Control and Prevention's (CDC) data collection and public awareness efforts for sickle cell disease and related hemoglobinopathies. The program aims to improve access to comprehensive, coordinated, and lifelong care for affected individuals.
Proponents argue
Proponents argue that this legislation is crucial for addressing the significant health disparities and fragmented care experienced by individuals with sickle cell disease, a condition that disproportionately affects minority populations. They contend that establishing comprehensive treatment centers, facilitating pediatric-to-adult care transitions, and supporting community engagement will lead to better health outcomes, improved quality of life, and more equitable access to specialized care.
Opponents contend
No specific opposition arguments are readily apparent from the bill text. General concerns, if any, might revolve around the administrative costs of establishing new federal programs or the potential for an open-ended authorization of appropriations to lead to unchecked spending, though these are not explicitly stated in the provided context.
The bill is moderately detailed but logically structured, making it accessible for an informed reader to understand its core provisions and implications within a reasonable timeframe.
Section 2, new 330Q(b)
Program Establishment for Sickle Cell Disease Treatment Centers
This provision directs the Secretary of Health and Human Services to award grants to eligible entities to create "Sickle Cell Disease Treatment Centers." These centers will use a "hub-and-spoke" framework to provide coordinated, lifelong health care for sickle cell patients, improve pediatric-to-adult transitions, collect clinical data, and conduct public health awareness campaigns.
Supporters argue
Supporters argue this directly addresses the fragmented care often experienced by sickle cell patients, leading to better health outcomes and quality of life.
Critics contend
No specific opposition is typically raised against the general goal of improving care for a specific disease, though concerns about program design or cost might arise.
Tradeoffs
Balancing broad access with specialized care, ensuring equitable distribution of resources.
Section 2, new 330Q(a)(2), (3), (4) and (c)
Structure of Treatment Centers and Eligibility
This section defines the "hub-and-spoke network" as a system where a medical hub (hospital, clinic, university health center) manages a network of spokes (Federally-qualified health centers, hospitals, primary care providers) to deliver comprehensive sickle cell care. It also specifies that an "eligible entity" for grants must comprise such a network and at least one community-based nonprofit organization.
Section 2, new 330Q(d)(1)
Medical Hub Responsibilities and Activities
Medical hubs receiving grant funds are required to cover operating costs, comply with treatment guidelines, educate providers, provide integrated care (including primary, specialty, pain, mental health, genetic counseling), coordinate reproductive health services, provide a dedicated sickle cell expert, educate on social determinants of health and implicit bias, offer telehealth, implement pediatric-to-adult transition programs, provide social work/community health worker services, collect data, and engage in quality improvement.
Section 2, new 330Q(d)(2)
Community-Based Organization Responsibilities
Community-based organizations (CBOs) within eligible entities are to use grant funds to provide education and outreach to at-risk individuals, patients, and caregivers; address social determinants of health (food, housing, transportation); provide social work/community health worker services; coordinate sickle cell trait testing and genetic counseling; and engage in quality improvement.
Section 2, new 330Q(f)
Establishment and Duties of National Coordinating Center
The bill mandates the Secretary to establish or contract for a National Sickle Cell Disease Coordinating Center. This center will advise the Secretary on program design, develop a national strategy for equitable care, coordinate with federal agencies for data collection, maintain a comprehensive research and care strategy, establish a stakeholder panel, support hub-and-spoke frameworks, improve patient-centered care, provide technical assistance, and educate the public.
Section 2, new 330Q(g)
Enhanced CDC Data Collection and Public Awareness
This provision directs the CDC Director, in coordination with the National Coordinating Center, to collect, monitor, and distribute data, best practices, and findings from the grant activities. It also requires maintaining up-to-date data on sickle cell disease (including subtypes, health outcomes, complications), improving national incidence/prevalence data, identifying health disparities, assessing therapy utilization, and evaluating risk factors. Additionally, it mandates developing educational materials and public awareness campaigns.
Section 2, new 330Q(k)
Funding Authorization and Allocation
This section authorizes "such sums as may be necessary" for fiscal year 2027 and each fiscal year thereafter to carry out the entire program. It further specifies how appropriated funds should be allocated: 70% for hub-and-spoke networks, 20% for community-based organizations, 5% for the National Coordinating Center, and 5% for CDC data collection activities.
Eligible entities can use funds to identify and secure resources for reimbursement under Medicaid/CHIP and other health programs, and to assist patients with accessing health insurance, including potentially paying premiums and cost-sharing.
Section 2, new 330Q(d)(4)(A) and (B)
Why it matters:This is a practical, administrative detail for program sustainability and patient support, often placed in ancillary provisions rather than core program descriptions. It's standard legislative practice.
Case for: Supporters argue that ensuring long-term reimbursement and direct insurance assistance for patients is crucial for the program's sustainability and for reducing financial barriers to care for vulnerable populations.
Case against: Some might argue that direct payment of premiums or cost-sharing could create moral hazard or be an inefficient use of federal funds, preferring to focus solely on direct care provision.
Estimated impact: Potentially significant financial relief for patients and long-term financial stability for treatment centers.
Medical hubs are required to educate healthcare providers on social determinants of health and implicit bias that may affect the quality of care and life for patients with sickle cell disease or trait.
Section 2, new 330Q(d)(1)(H)
Why it matters:While critically important for equitable care, specific training mandates are often detailed within broader operational requirements. It's standard legislative practice.
Case for: Proponents argue that addressing implicit bias and social determinants of health is fundamental to improving health equity and ensuring that sickle cell patients receive unbiased, high-quality care that considers their full life circumstances.
Case against: Some might argue that such training is outside the primary clinical mission of treatment centers or that its effectiveness is difficult to measure, though direct opposition is unlikely.
Estimated impact: Potential for significant improvement in patient experience and reduction of health disparities through more culturally competent care.
In awarding grants, the Secretary "may give priority" to eligible entities that include at least one Historically Black College or University (HBCU) or Minority Serving Institution (MSI) with a relevant health-related program (medical, nursing, genetic counseling, social work).
Section 2, new 330Q(e)(3)(A)
Why it matters:Priority considerations are often placed in selection criteria rather than main program descriptions. It's standard legislative practice.
Case for: Supporters argue this priority promotes health equity, builds capacity in institutions that historically serve minority populations disproportionately affected by sickle cell disease, and fosters a diverse healthcare workforce.
Case against: Some might argue that prioritizing institutions based on designation rather than solely on merit or geographic need could be less efficient, though direct opposition is unlikely given the context of health disparities.
Estimated impact: Potential to strengthen healthcare infrastructure and training in underserved communities and institutions.